SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated...

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis – Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...